Literature DB >> 31617799

Evolution of Transarterial Chemoembolization for the Treatment of Liver Cancer.

Kyung Won Kim1, Annick D Van den Abbeele1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31617799      PMCID： PMC6900203          DOI： 10.1148/radiol.2019192090

Source DB:  PubMed          Journal:  Radiology        ISSN： 0033-8419            Impact factor:   29.146


× No keyword cloud information.
  10 in total

1.  Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-08-23       Impact factor: 11.740

2.  Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.

Authors:  Masatoshi Kudo; Kazuho Imanaka; Nobuyuki Chida; Kohei Nakachi; Won-Young Tak; Tadatoshi Takayama; Jung-Hwan Yoon; Takeshi Hori; Hiromitsu Kumada; Norio Hayashi; Shuichi Kaneko; Hirohito Tsubouchi; Dong Jin Suh; Junji Furuse; Takuji Okusaka; Katsuaki Tanaka; Osamu Matsui; Michihiko Wada; Iku Yamaguchi; Toshio Ohya; Gerold Meinhardt; Kiwamu Okita
Journal:  Eur J Cancer       Date:  2011-09       Impact factor: 9.162

Review 3.  New concepts in embolotherapy of HCC.

Authors:  F Pesapane; N Nezami; F Patella; J F Geschwind
Journal:  Med Oncol       Date:  2017-03-16       Impact factor: 3.064

4.  Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.

Authors:  Tim Meyer; Richard Fox; Yuk Ting Ma; Paul J Ross; Martin W James; Richard Sturgess; Clive Stubbs; Deborah D Stocken; Lucy Wall; Anthony Watkinson; Nigel Hacking; T R Jeffry Evans; Peter Collins; Richard A Hubner; David Cunningham; John Neil Primrose; Philip J Johnson; Daniel H Palmer
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-06-23

5.  Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma: usefulness of contrast saturation features on cone-beam computed tomography imaging for predicting short-term tumor response.

Authors:  Jung Suk Oh; Ho Jong Chun; Byung Gil Choi; Hae Giu Lee
Journal:  J Vasc Interv Radiol       Date:  2013-02-26       Impact factor: 3.464

6.  Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis.

Authors:  Ping Zhan; Qian Qian; Li-Ke Yu
Journal:  Hepatobiliary Surg Nutr       Date:  2013-08       Impact factor: 7.293

7.  First Human Experience with Directly Image-able Iodinated Embolization Microbeads.

Authors:  Elliot B Levy; Venkatesh P Krishnasamy; Andrew L Lewis; Sean Willis; Chelsea Macfarlane; Victoria Anderson; Imramsjah Mj van der Bom; Alessandro Radaelli; Matthew R Dreher; Karun V Sharma; Ayele Negussie; Andrew S Mikhail; Jean-Francois H Geschwind; Bradford J Wood
Journal:  Cardiovasc Intervent Radiol       Date:  2016-05-20       Impact factor: 2.740

8.  Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

Authors:  Riccardo Lencioni; Josep M Llovet; Guohong Han; Won Young Tak; Jiamei Yang; Alfredo Guglielmi; Seung Woon Paik; Maria Reig; Do Young Kim; Gar-Yang Chau; Angelo Luca; Luis Ruiz Del Arbol; Marie-Aude Leberre; Woody Niu; Kate Nicholson; Gerold Meinhardt; Jordi Bruix
Journal:  J Hepatol       Date:  2016-01-22       Impact factor: 25.083

9.  Vandetanib-eluting Radiopaque Beads: Pharmacokinetics, Safety, and Efficacy in a Rabbit Model of Liver Cancer.

Authors:  Rafael Duran; Julien Namur; Florentina Pascale; Peter Czuczman; Zainab Bascal; Hugh Kilpatrick; Rhys Whomsley; Samantha Ryan; Andrew L Lewis; Alban Denys
Journal:  Radiology       Date:  2019-10-15       Impact factor: 11.105

Review 10.  Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC).

Authors:  Pedro Viveiros; Ahsun Riaz; Robert J Lewandowski; Devalingam Mahalingam
Journal:  Cancers (Basel)       Date:  2019-07-31       Impact factor: 6.639
  10 in total
  1 in total

1.  Homoharringtonine Exerts Anti-tumor Effects in Hepatocellular Carcinoma Through Activation of the Hippo Pathway.

Authors:  Haina Wang; Rui Wang; Dan Huang; Sihan Li; Beibei Gao; Zhijie Kang; Bo Tang; Jiajun Xie; Fanzhi Yan; Rui Liang; Hua Li; Jinsong Yan
Journal:  Front Pharmacol       Date:  2021-02-24       Impact factor: 5.810
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.